HighTower Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-2,500
Closed -$1.26K 3773
2025
Q3
$1.26K Buy
+2,500
New +$284K ﹤0.01% 3766
2024
Q1
Sell
-100
Closed -$1.88K 3772
2023
Q4
$1.88K Buy
100
+98
+4,900% +$7.63K ﹤0.01% 3513
2023
Q3
$2.23K Sell
2
-1
-33% -$77 ﹤0.01% 3463
2023
Q2
$1.09K Buy
+3
New +$239 ﹤0.01% 3381
2023
Q1
Sell
-1
Closed -$2.02K 3520
2022
Q4
$2.02K Sell
1
-1
-50% -$79 ﹤0.01% 3260
2022
Q3
$1K Buy
+2
New +$126 ﹤0.01% 3115
2022
Q1
Sell
-1
Closed -$2K 3511
2021
Q4
$2K Sell
1
-99
-99% -$6.82K ﹤0.01% 3237
2021
Q3
$1K Buy
+100
New +$7.03K ﹤0.01% 3125
2014
Q2
Sell
-300
Closed -$1K 1640
2014
Q1
$1K Buy
+300
New +$23.5K ﹤0.01% 1573

Other funds holding GILD

HighTower Advisors's GILD Position: Q1 2026 in Review

HighTower Advisors reduced its Gilead Sciences (GILD) stake by 13% in Q1 2026, selling an estimated $29.6M and leaving 1,450,177 shares worth $202M. The position accounts for 0.21% of the portfolio, ranked #96.

HighTower Advisors first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $204M in Q4 2025. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • HighTower Advisors held 1,450,177 shares of Gilead Sciences worth $202M as of Q1 2026.
  • HighTower Advisors sold 211,178 Gilead Sciences shares in Q1 2026, an estimated $29.6M.
  • Gilead Sciences made up 0.21% of HighTower Advisors's portfolio in Q1 2026, its #96 holding.
  • HighTower Advisors first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • HighTower Advisors's Gilead Sciences position peaked at $204M in Q4 2025.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.